Literature DB >> 12635658

Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway.

Asha Das1, Wan-Loo Tan, Jennifer Teo, Duncan R Smith.   

Abstract

In Singapore astrocytic tumours occur in only 25% of patients with primary brain tumours compared to 40-60% in other series. Glioblastoma multiforme arises either de novo as a primary glioblastomas associated with epidermal growth factor receptor (EGFR) and mdm2 over-expression or as a secondary glioblastomas, through malignant progression from low-grade astrocytomas, associated with p53 mutations and PDGFR-alpha over-expression. Using immunohistochemical methods and DNA sequencing, we studied our population of glioblastomas for overexpression of EGFR, mdm2, p53, and PDGFR-alpha as well directly for mutations of the p53 gene. While levels of over-expression of EGFR and mdm2 were consistent with levels expected for primary glioblastomas, levels of p53 and PDGFR-alpha were consistent with levels documented for secondary glioblastomas. Notably 96% of the samples over-expressed p53 as detected with monoclonal antibody pAb 240. Of the 39 samples available for DNA sequencing 18% (7/39) had p53 mutations, including three mutations previously undocumented in glioblastomas. These results provide strong evidence that glioblastomas in Asian patients do not conform to currently accepted models of glioblastoma development, and that clinically defined glioblastomas in these patients show genetic changes consistent with both 'primary' and 'secondary' glioblastomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12635658     DOI: 10.1023/a:1020622415786

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  Amplification and overexpression of MDM2 in primary (de novo) glioblastomas.

Authors:  W Biernat; P Kleihues; Y Yonekawa; H Ohgaki
Journal:  J Neuropathol Exp Neurol       Date:  1997-02       Impact factor: 3.685

2.  Racial comparison of p53 alterations in breast cancer: difference in prognostic value.

Authors:  Y H Shiao; V W Chen; X C Wu; W D Scheer; H P Lehmann; G T Malcom; D A Boudreau; B Ruiz; P Correa
Journal:  In Vivo       Date:  1996 Mar-Apr       Impact factor: 2.155

3.  Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails.

Authors:  A J Ekstrand; N Sugawa; C D James; V P Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

4.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

5.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

6.  Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.

Authors:  K Watanabe; O Tachibana; K Sata; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Brain Pathol       Date:  1996-07       Impact factor: 6.508

7.  p53 gene mutation: software and database.

Authors:  C Béroud; T Soussi
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

8.  Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas.

Authors:  M Hermanson; K Funa; J Koopmann; D Maintz; A Waha; B Westermark; C H Heldin; O D Wiestler; D N Louis; A von Deimling; M Nistér
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

9.  Subsets of glioblastoma multiforme defined by molecular genetic analysis.

Authors:  A von Deimling; K von Ammon; D Schoenfeld; O D Wiestler; B R Seizinger; D N Louis
Journal:  Brain Pathol       Date:  1993-01       Impact factor: 6.508

10.  Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker.

Authors:  S J Chia; W Y Tang; J Elnatan; W M Yap; H S Goh; D R Smith
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

View more
  17 in total

1.  Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.

Authors:  C Haberler; E Gelpi; C Marosi; K Rössler; P Birner; H Budka; J A Hainfellner
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

2.  Glioblastoma multiforme outcomes of 107 patients treated in two Singapore institutions.

Authors:  Song Tao Timothy Cheo; Gek Hsiang Lim; Keith Hsiu Chin Lim
Journal:  Singapore Med J       Date:  2016-02-26       Impact factor: 1.858

3.  Definitive chemoradiation at high volume facilities is associated with improved survival in glioblastoma.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Neurooncol       Date:  2017-07-07       Impact factor: 4.130

4.  Redox-Active Mn Porphyrin-based Potent SOD Mimic, MnTnBuOE-2-PyP(5+), Enhances Carbenoxolone-Mediated TRAIL-Induced Apoptosis in Glioblastoma Multiforme.

Authors:  Yulyana Yulyana; Artak Tovmasyan; Ivy A W Ho; Kian Chuan Sia; Jennifer P Newman; Wai Hoe Ng; Chang Ming Guo; Kam Man Hui; Ines Batinic-Haberle; Paula Y P Lam
Journal:  Stem Cell Rev Rep       Date:  2016-02       Impact factor: 5.739

5.  Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis.

Authors:  Sudheer R Thumma; Robert K Fairbanks; Wayne T Lamoreaux; Alexander R Mackay; John J Demakas; Barton S Cooke; Ameer L Elaimy; Peter W Hanson; Christopher M Lee
Journal:  World J Surg Oncol       Date:  2012-05-03       Impact factor: 2.754

6.  Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007.

Authors:  Robert Dubrow; Amy S Darefsky
Journal:  BMC Cancer       Date:  2011-07-29       Impact factor: 4.430

7.  Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.

Authors:  Dawn Q Chong; Xin Y Toh; Ivy A W Ho; Kian C Sia; Jennifer P Newman; Yulyana Yulyana; Wai-Hoe Ng; Siang H Lai; Mac M F Ho; Nivedh Dinesh; Chee K Tham; Paula Y P Lam
Journal:  BMC Cancer       Date:  2015-04-11       Impact factor: 4.430

8.  Genomic and Molecular Characterization of Brain Tumors in Asian and Non-Asian Patients of Los Angeles: A Single Institution Analysis.

Authors:  Courtney Duong; Thien Nguyen; John P Sheppard; Vera Ong; Lawrance K Chung; Daniel T Nagasawa; Isaac Yang
Journal:  Brain Tumor Res Treat       Date:  2017-10-31

9.  Leveraging ethnic group incidence variation to investigate genetic susceptibility to glioma: a novel candidate SNP approach.

Authors:  Daniel I Jacobs; Kyle M Walsh; Margaret Wrensch; John Wiencke; Robert Jenkins; Richard S Houlston; Melissa Bondy; Matthias Simon; Marc Sanson; Konstantinos Gousias; Johannes Schramm; Marianne Labussière; Anna Luisa Di Stefano; H-Erich Wichmann; Martina Müller-Nurasyid; Stefan Schreiber; Andre Franke; Susanne Moebus; Lewin Eisele; Andrew T Dewan; Robert Dubrow
Journal:  Front Genet       Date:  2012-10-12       Impact factor: 4.599

10.  Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage.

Authors:  F S Pardo; D W Hsu; R Zeheb; J T Efird; P G Okunieff; D M Malkin
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.